Key result
This review discusses the clinical utility and phase III trials of the azilsartan-chlorthalidone fixed combination for the management of hypertension.
Why the study?
Does azilsartan-chlorthalidone fixed combination improve blood pressure-lowering effects in patients with hypertension?
Does azilsartan-chlorthalidone fixed combination improve blood pressure-lowering effects in patients with hypertension?
The azilsartan-chlorthalidone fixed combination offers a novel and potentially more effective antihypertensive option by pairing a potent ARB with chlorthalidone.
Azilsartan-chlorthalidone offers enhanced BP lowering as first ARB-chlorthalidone pair; extends trial data on chlorthalidone-based regimens.
Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique because it is the first to partner an ARB with this, possibly more effective, diuretic. This review will address trials involving both components of this drug, as well as phase III trials involving the fixed-combination product. The article will also discuss the benefit of combination therapy in the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Shuster et al. (2012) conducted a review in Hypertension. Azilsartan-chlorthalidone fixed combination was evaluated. This review discusses the clinical utility and phase III trials of the azilsartan-chlorthalidone fixed combination for the management of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: